Iovance Biotherapeutics, Inc. (1IOVA)
MTA
7.27
+0.24 (+3.41%)
Closed
Aug 25, 2026
Day's Range
6.897.27
52 wk Range
1.517.90
Financial Statements - 1IOVA - Iovance Biotherapeutics, Inc.
Revenue
263.50M▲ 89.6%
Net Income
-390.97M▼ 24.0%Net Margin -148.4%
EBITDA
-345.74M▼ 16.1%
Free Cash Flow
-336.24M▼ 9.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | 263.50M | 138.97M |
| Cost of Goods | 173.18M | 105.03M |
| Gross Profit | 90.31M | 33.94M |
 Operating Expense | - | - |
| Operating Income | -398.21M | -334.82M |
| Non-Operating Interest | - | - |
| Other Income Expense | -5.14M | - |
| Pre Tax Income | -393.04M | -317.65M |
| Income Tax | -2.07M | -2.39M |
| Net Income | -390.97M | -315.25M |
| EPS Basic | -1.09 | -1.28 |
| EPS Diluted | -1.094119 | -1.28 |
| Basic Shares Outstanding | 357.34M | 245.54M |
| Diluted Shares Outstanding | 357.34M | 245.54M |
| Ebit | -398.21M | -334.82M |
| Ebitda | -345.74M | -297.88M |
| Net Income Continuous Operations | -390.97M | -315.25M |
| Minority Interests | - | - |
| Preferred Stock Dividends | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
